|
gptkbp:instanceOf
|
gptkb:company
|
|
gptkbp:CEO
|
gptkb:Abraham_Heifets
|
|
gptkbp:collaboratedWith
|
gptkb:Bayer
gptkb:Janssen_Biotech
gptkb:Merck
gptkb:Hansoh_Pharma
|
|
gptkbp:foundedYear
|
2012
|
|
gptkbp:founder
|
gptkb:Abraham_Heifets
gptkb:Izhar_Wallach
|
|
gptkbp:fundedBy
|
gptkb:Series_B
over $174 million
|
|
gptkbp:headquartersLocation
|
gptkb:San_Francisco,_California,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Atomwise
|
|
gptkbp:industry
|
gptkb:artificial_intelligence
gptkb:biotechnology
drug discovery
|
|
gptkbp:investor
|
gptkb:DCVC
gptkb:Tencent
gptkb:Y_Combinator
gptkb:B_Capital_Group
|
|
gptkbp:mission
|
to use AI for faster, safer, and more effective drug discovery
|
|
gptkbp:notableAchievement
|
pioneered use of deep learning for drug discovery
|
|
gptkbp:notableProduct
|
gptkb:AtomNet
|
|
gptkbp:numberOfEmployees
|
100-200 (as of 2023)
|
|
gptkbp:specializesIn
|
AI-driven drug discovery
|
|
gptkbp:technology
|
deep learning
structure-based drug design
|
|
gptkbp:website
|
https://www.atomwise.com/
|
|
gptkbp:bfsParent
|
gptkb:OS_Fund
gptkb:Samir_Kaul
gptkb:B_Capital_Group
|
|
gptkbp:bfsLayer
|
6
|